Executive summary of the 2018 KDIGO Hepatitis C in CKD Guideline: welcoming advances in evaluation and management
Executive summary of the 2018 KDIGO Hepatitis C in CKD Guideline: welcoming advances in evaluation and management
复制标题
DOI：
10.1016/j.kint.2018.06.011
复制
发表时间：
2018-10-01
影响因子：
19.6
通讯作者：
Martin, Paul
中科院分区：
文献类型：
--
作者：
Jadoul, Michel;Berenguer, Marina C.;Martin, Paul
慢性肾脏疾病(CKD)患者，包括接受透析治疗和肾脏移植的患者，感染丙型肝炎病毒(HCV)会对肝脏、肾脏和心血管造成不良后果。自2008年发表最初的肾脏疾病：改善全球结局(KDIGO)丙型肝炎病毒指南以来，丙型肝炎病毒管理方面的重大进展，特别是随着直接作用抗病毒疗法的出现，现在已经使慢性肾脏病患者治愈丙型肝炎成为可能。此外，诊断技术已经发展到能够对肝纤维化进行非侵入性诊断。因此，工作组对CKD指南中的KDIGO丙型肝炎进行了全面的审查和更新。本执行摘要重点介绍了准则建议的关键方面。
Infection with the hepatitis C virus (HCV) has adverse liver, kidney, and cardiovascular consequences in patients with chronic kidney disease (CKD), including those on dialysis therapy and in those with a kidney transplant. Since the publication of the original Kidney Disease: Improving Global Outcomes (KDIGO) HCV Guideline in 2008, major advances in HCV management, particularly with the advent of direct-acting antiviral therapies, have now made the cure of HCV possible in CKD patients. In addition, diagnostic techniques have evolved to enable the noninvasive diagnosis of liver fibrosis. Therefore, the Work Group undertook a comprehensive review and update of the KDIGO HCV in CKD Guideline. This Executive Summary highlights key aspects of the guideline recommendations.